Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 3Withdrawn 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 8Azacitidine 8fludarabine phosphate 6fludarabine 6Peripheral Blood Stem Cell Transplantation 6Whole-Body Irradiation 5Methotrexate 5Cyclosporine 5Busulfan 5Decitabine 4Tacrolimus 3Mycophenolic Acid 3Filgrastim 3Cytarabine 3AP 1903 reagent 3venetoclax 2magrolimab 2Stem Cell Transplantation 2Specimen Handling 2Sirolimus 2Saline Solution 2Radiotherapy 2Nivolumab 2Cyclosporins 2Biopsy 2Alemtuzumab 2tumor-cells apoptosis factor, human 1sabatolimab 1ponatinib 1plerixafor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Myelodysplastic Syndromes × olutasidenib × Clear all
NCT04013880 2020-07-07

ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

Vanderbilt-Ingram Cancer Center

Phase 1/2 Withdrawn
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡